<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228238</url>
  </required_header>
  <id_info>
    <org_study_id>ANOVA</org_study_id>
    <nct_id>NCT03228238</nct_id>
  </id_info>
  <brief_title>ANti-Oxidant in Variant Angina (ANOVA) Trial</brief_title>
  <official_title>Effects of Long-term Vitamin C+E and Statin Therapy on Vasospasm Improvement and Regression of Atheroma in Patients With Variant Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose Objectives

        1. To evaluate the anti-oxidant effect of long-term Vitamin C+E therapy on coronary
           vasospasm improvement.

        2. To evaluate the anti-oxidant effect of long-term statin therapy on coronary vasospasm
           improvement.

        3. To evaluate the effect of long-term Vitamin C+E and statin therapy on regression of
           atheroma in target coronary vessels via intravascular ultrasound.

        4. To find out the role of vascular endothelium in variant angina via evaluating long-term
           Vitamin C+E and statin therapy on improvement in vascular endothelial function by
           assessing brachial arterial expansion capability.

        5. To find out the role of vascular endothelium in variant angina via evaluating long-term
           Vitamin C+E and statin therapy on improvement in arterial stiffness by assessing pulse
           wave velocity(PWV)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Prospective, open label, Four-arm, randomized single-center trial to test the
      effect long-term Vitamin C+E and Statin therapy on vasospasm improvement and regression of
      atheroma in patients with variant angina.

      After provocation test, patients will be classified into three groups.(See below)

        1. Negative group : Patients who have symptoms that are consistent with vasospastic angina
           but only show luminal narrowing less than 50% on coronary angiography during provocation
           test.

        2. Mild Spastic group : Patients who have symptoms that are consistent with vasospastic
           angina and show luminal narrowing over 50% to less than 90% on coronary angiography
           during provocation test.

        3. Severe Spastic group : Patients who have symptoms that are consistent with vasospastic
           angina and show luminal narrowing over 90% on coronary angiography during provocation
           test.

      In each group (except for patient in Negative group), patients will be randomized in a two by
      two factorial manner according to the study drug therapy (Vitamin C+E vs. no Vitamin C+E)
      (Statin vs. no Statin) As a result, patients in each group(except for patient in Negative
      group) will be randomized to 4 treatment subgroups, which are

        1. Control subgroup : Standard medication for Variant angina only

        2. Vitamin subgroup : Standard medication + Vitamin C+E

        3. Statin subgroup : Standard medication + Statin

        4. Dual subgroup : Standard medication + Vitamin C+E + Statin

      Patients in Negative group will be prescribed only for standard medication for variant
      angina.

      Patient Enrollment: Recruiting 300 patients(100 patients for each group, as 25 patients for
      each subgroups) from September 2014 through February 2021 at single center in Korea(Seoul
      National University Hospital)

      Patient Follow-Up: Clinical follow-up will occur at 1, and 6 months, and at 2, 4, and 6
      years. Investigator or designee may conduct follow-up as telephone contacts or office visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasospasm at 6months</measure>
    <time_frame>at 6 months</time_frame>
    <description>Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasospasm at 2 years</measure>
    <time_frame>at 2 years</time_frame>
    <description>Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasospasm at 4 years</measure>
    <time_frame>at 4 years</time_frame>
    <description>Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasospasm at 6 years</measure>
    <time_frame>at 6 years</time_frame>
    <description>Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Vasospasm</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>Changes of Vasospasm in Control subgroup, Vitamin subgroup, Statin subgroup, and Dual subgroup compared to baseline vasospasm assessed by provocation test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composed improvement of Vascular endothelial function(Brachial arterial expansion capability)</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Vascular endothelial function(Brachial arterial expansion capability)</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to baseline endothelial function test results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of improvement of Vascular endothelial function(Brachial arterial expansion capability)</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>in Vitamin subgroup, Statin subgroup, and Dual subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composed improvement of Arterial stiffness(Pulse wave velocity(PWV))</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Arterial stiffness(Pulse wave velocity(PWV))</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to baseline endothelial function test results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of improvement of Arterial stiffness(Pulse wave velocity(PWV))</measure>
    <time_frame>at 6 months, and at 2, 4, and 6 years follow up period</time_frame>
    <description>in Vitamin subgroup, Statin subgroup, and Dual subgroup</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Variant Angina</condition>
  <arm_group>
    <arm_group_label>Dual subgroup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin subgroup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin subgroup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control subgroup : Standard medication for Variant angina only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C and Vitamin E</intervention_name>
    <description>Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU</description>
    <arm_group_label>Dual subgroup</arm_group_label>
    <arm_group_label>Vitamin subgroup</arm_group_label>
    <other_name>Ascorbic acid and Tocopherol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Atorvastatin calcium 10mg</description>
    <arm_group_label>Dual subgroup</arm_group_label>
    <arm_group_label>Statin subgroup</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard medication for variant angina</intervention_name>
    <description>Calcium Channel blocker or NG</description>
    <arm_group_label>Dual subgroup</arm_group_label>
    <arm_group_label>Statin subgroup</arm_group_label>
    <arm_group_label>Vitamin subgroup</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Calcium Channel blocker or NG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 30 years of age.

          2. Subject is able to verbally confirm understandings of risks, benefits and treatment
             alternatives of receiving the Vitamin C+E or Statin or Dual, and he/she or his/her
             legally authorized representative provides written informed consent prior to any study
             related procedure.

          3. Subject must have symptoms that are consistent with vasospastic angina with planned
             Coronary angiography and Provocation test.

        Exclusion Criteria:

          1. Patient who has organic coronary stenosis in main coronary branch at least 50% luminal
             narrowing after intracoronary nitroglycerin injection

          2. Patient who has continuously taken Vitamin C or Vitamin E or Statin within 3months
             before Admission

          3. Creatinine level â‰¥ 2.0mg/dL or dependence on dialysis.

          4. Severe hepatic dysfunction (AST and ALT: 3 times upper normal reference values).

          5. Active Myopathy or elevated Creatine kinase enzyme level (3 times upper normal
             reference values).

          6. History of Severe hepatic dysfunction or Rhabdomyolysis due to statin side effect

          7. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study.

          8. History of Urolithiasis

          9. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <phone>82-2-2072-2226</phone>
    <email>hyosoo@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Soo Kim, M.D., PhD</last_name>
      <phone>82-2-2072-2226</phone>
      <email>hyosoo@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Soo Kim</investigator_full_name>
    <investigator_title>Director of Cardiac Catheterization Laboratory &amp; Coronary Intervention</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina Pectoris, Variant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

